Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 12/20 | 0.47 |
| ▸ | MGAM | O43451 | 11/20 | 0.47 |
| ▸ | SI | P14410 | 11/20 | 0.47 |
| ▸ | MGAM2 | Q2M2H8 | 11/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165678 | 0.94 | GAA (0.49) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6697051 | 0.90 | GAA (0.52) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6696915 | 0.89 | GAA (0.43) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6692363 | 0.88 | MGAM (0.50) | GAAMGAMSIMGAM2ALOX5 | |
| SCHEMBL6697592 | 0.88 | GAA (0.45) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6692286 | 0.88 | GAA (0.52) | GAAMGAMSIMGAM2MAPT | |
| SCHEMBL6698722 | 0.88 | MGAM (0.54) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6170334 | 0.87 | IMPDH2 (0.45) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6696940 | 0.86 | ALDH1A1 (0.49) | GAAMGAMSIMGAM2KMT2A | |
| SCHEMBL6693998 | 0.86 | MGAM (0.41) | GAAMGAMSIMGAM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138284-A1 | Indol-3-yl derivatives | WIESNER MATTHIAS | 2004-07-15 | — | — | US | disclosed |
| US-6743810-B2 | INTEGRIN INHIBITORS; TUMORS, OSTEOPOROSIS, OSTEOLYTIC DISEASES, SUPPRESSING ANGIOGENESIS, ANTITHROMBOTIC | MERCK PATENT GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | MERCK PATENT GMBH (DE) | 2003-03-06 | — | — | US | disclosed |
| EP-1254133-A2 | INDOL-3-YL DERIVATIVES | MERCK PATENT GmbH (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058893-A2 | INDOL-3-YL DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | IGF1R, IDO1, ITGB3 | GAA 3469/4885MGAM 811/4885SI 121/4885 |
| US-20040138284-A1 | Indol-3-yl derivatives | ITGB3, ITGB1, IGF1R | GAA 3882/4885MGAM 1542/4885SI 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.